AbbVie expands siRNA push with $335m ADARx deal
This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.
This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.